Flexion Therapeutics Inc. said on Tuesday its lead drug met the main goal of reducing pain in patients with moderate to severe osteoarthritis knee pain in a late-stage study.
Osteoarthritis is a form of degenerative arthritis affecting 27 million Americans. It is caused by the progressive breakdown and eventual loss of cartilage in one or more joints.
The material has been provided by InstaForex Company – www.instaforex.com
Flexion Therapeutics Inc. said on Tuesday its lead drug met the main goal of reducing pain in patients with moderate to severe osteoarthritis knee pain in a late-stage study.
Osteoarthritis is a form of degenerative arthritis affecting 27 million Americans. It is caused by the progressive breakdown and eventual loss of cartilage in one or more joints.
The material has been provided by InstaForex Company – www.instaforex.com
Related Posts: